MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that the Centers for Medicare and Medicaid Services (CMS) has issued its proposed new, bundled, third quarter 2007 payment amount for XOPENEX® (levalbuterol HCl) Inhalation Solution and generic albuterol inhalation solution products. The new Medicare Part B reimbursement rate announced by CMS is $0.525 per 0.5 mg of levalbuterol and $0.525 per 1 mg of generic albuterol. This translates into $1.31 per unit dose for the 1.25 mg dose of XOPENEX Inhalation Solution, which is the dose of XOPENEX Inhalation Solution most commonly used by Medicare Part B beneficiaries. This reimbursement rate is expected to go into effect on July 1, 2007.
